Further reading

This WHO Centre’s website serves as an information platform. We are thus pleased to provide studies and documents of interest from other institutions in this field.

2017

Wild C, Zechmeister-Koss I, Vogler S.: Risk-sharing Schemes und weitere Managed-Entry Agreements: Sind vertrauliche Abkommen zielführend oder kontraproduktiv? . [Title translated in English: Risk-sharing schemes and further managed entry Agreements: are confidential agreements fulfilling their target or are they counterproductive?], In: Ludwig Boltzmann Institut Health Technology Assessment, Newsletter Februar 2017: Nr. 154 , 2017, Vienna

OECD: Tackling Wasteful Spending on Health. 2017

OECD: New Health Technologies: Managing Access, Value and Sustainability . 2017

2016

WHO Regional Office for Europe: Challenges and opportunities in improving access to medicines through efficient public procurement in the WHO European Region. 2016, Copenhagen

Wirtz V, Hogerzeil H, Gray A, Bigdeli M, de Joncheere C, Ewen M and others: Essential medicines for universal health coverage. In: The Lancet, Vol. 389, No. 10067: , 2016

2015

WHO Regional Office for Europe: Access to new medicines in Europe: technical review of policy initiatives and opportunities for collaboration and research. 2015

2014

Vogler S.: Liberalization in the Pharmacy Sector. In: OECD Global Forum on Distribution 2014, 2014, Paris

2013

Paris V, Belloni A.: Value in Pharmaceutical Pricing. In: OECD Health Working Papers 2013, No. 63: , 2013

Bouvy J, Vogler S: Priority Medicine Report. Background Paper 8.3. Pricing and Reimbursement Policies: Impacts on Innovation. In: WHO 2013, 2013

Kaplan W, Wirtz V, Mantel Teuwisse A, Laing R.: Priority medicines for Europe and the world - 2013 update. In: WHO 2013, 2013

Ferrario A, Kanavos P.: Managed entry agreements for pharmaceuticals: The European experience. In: The London School of Economics and Political Science 2013, 2013

Aricks F, Bucics A, Habl C.: Process on Corporate Social Responsibility in the Field of Pharmaceuticals; Platform on Access to Medicines in Europe; Final Report of the Working Group on Mechanism of Coordinated Access to Orphan Medicinal Products. In: MoCA-OMP 2013, 2013, Brussels

2012

Carone G, Schwierz C, Xavier A.: Cost-containment policies in public pharmaceutical spending in the EU. Commissioned by the European Commission, Directorate-General for Economic and Financial Affairs (Ed.), In: Brussels 2012 Economic Papers 461, 2012, Brussels

2011

Vogler S, Habl C, Leopold C, Morak S, Zimmermann N.: Pharmaceutical Health Information (PHIS) Final Technical Report. Pharmaceutical Health Information System; Written by ÖBIG, commissioned by the Executive Agency for Health and Consumers and the Austrian Federal Ministry of Health, In: Utrecht WHO Collaborating Centre for Pharmacoepidemiology and Pharmaceutical Policy 2011, 2011

Hoebert J, Mantel-Teuwisse A.: Pharmaceutical Health Information (PHIS) Evaluation Report. Complied in the framework of the Pharmaceutical Health Information System Project, In: Utrecht WHO Collaborating Centre for Pharmacoepidemiology and Pharmaceutical Policy 2011, 2011

Vogler S, Morak S.: Pharmaceutical Health Information (PHIS) Evaluation Report: Technical Interim Report. Pharmaceutical Health Information System; Written by ÖBIG, commissioned by the Executive Agency for Health and Consumers and the Austrian Federal Ministry of Health, 2011

Executive Agency of Health and Consumers (EAHC): EU Health Programme: working together to improve public health in Europe – A selection of Public Health Projects with an important impact for EU Member States”. In collaboration with the Health Programme’s National Focal Points (NFP) and the Directorate General for Health and Consumers (DG SANCO) , 2011

Kanavos P, Schurer W, Vogler S.: The Pharmaceutical Distribution Chain in the European Union: Structure and Impact on Pharmaceutical Prices. London School of Economics, Gesundheit Österreich GmbH; Commissioned by the European Commission, Directorate-General Enterprise, 2011

Kanavos P, Nicod E, Espin J, an den Aardweg S. : Short- and Long-Term Effects of Value-Based Pricing vs. External Price Referencing. London School of Economics, Andalusian School of Public Health; Commissioned by the European Commission, Directorate-General Enterprise, 2011

Espín J, Rovira J, García L.: Experiences and Impact of European Risk-Sharing Schemes Focusing on Oncology Medicines. Andalusian School of Public Health ; Commissioned by the European Commission, Directorate-General Enterprise, 2011

2009

Kanavos P, Seeley L, Vandoros S, Aardweg S. : Tender systems for outpatient pharmaceuticals in the European Union: Evidence from the Netherlands, Germany and Belgium. London School of Economics; Commissioned by the European Commission, Directorate-General Enterprise, 2009

2008

OECD Health Policy Studies: Pharmaceutical Pricing Policies in a Global Market. Commissioned by the Organisation for Economic Co-operation and Development, 2008

2007

Espín J, Rovira J.: Analysis of differences and commonalities in pricing and reimbursement systems in Europe. Andalusian School of Public Health; Commissioned by the European Commission, Directorate-General Enterprise, 2007

2006

Vogler S, Habl C.: Pharmaceutical Pricing and Reimbursement Information (PPRI): Technical Interim Report. Commissioned by the European Commission, Directorate-General Health and Consumer Protection and Austrian Federal Ministry of Health, Family and Youth, 2006